One of the purposes of an investigation by Porcellini et al. (A-19) was to investigate the effect on CD4 T cell count of administration of intermittent interleukin (IL-2) in addition to highly active antiretroviral therapy (HAART). The following table shows the CD4 T cell count at baseline and then again after 12 months of HAART therapy with IL-2. Do the data show, at the .05 level, a significant change in CD4 T cell count?

Subject 1 2 3 4 5 6 7

CD4 T cell count at entry ( 10⁶/L) 173 58 103 181 105 301 169

CD4 T cell count at end of follow-up ( 10⁶/L) 257 108 315 362 141 549 369